The company used a replication-incompetent adenovirus type 5 (Ad5) vector to deliver two payloads, the pathogen antigen and adjuvant, to the cells of the mucosal epithelium of the small bowel. The vaccine includes both spike and nucleocapsid SARS-CoV-2 proteins.

The tablet was generally well-tolerated and immunogenic, as measured by multiple markers of immune response to SARS-CoV-2 antigens. Also, the vaccine induced potent CD8⁺ (cytotoxic) T-cell responses, and is potentially protective against new and emerging COVID-19 strains, according to early data.

No serious adverse events were reported during the trial.

"We expect that our vaccine will be less impacted by new variants than injectable vaccines," said Sean Tucker, PhD, Vaxart's chief scientific officer.

Centaur Biopharma to manufacture COVID-19 vaccine for Vaxart
Centaur Biopharmaceutical Services has expanded its manufacturing agreement with Vaxart to manufacture Vaxart's oral COVID-19 vaccine.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...